Safety and Efficacy of Subcutaneously Administered Efalizumab in Adults with Moderate-to-Severe Hand and Foot PsoriasisAn Open-Label Study

被引：0
|
作者：
Rajat Varma
Jennifer A. Cafardi
Wendy Cantrell
Craig Elmets
机构：
[1] University of Alabama Medical Center,UAB Department of Dermatology
来源：
American Journal of Clinical Dermatology | 2008年 / 9卷
关键词：
Psoriasis; Plaque Psoriasis; Dermatology Life Quality Index; Acitretin; Efalizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Introduction: Hand and foot psoriasis may be more disabling than psoriasis at other body locations because of its interference with daily functional activities. Most treatment options have limited efficacy, short duration of response, toxicity, intolerability, or inconvenience.
引用
收藏
页码：105 / 109
页数：4
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY OF OPEN-LABEL MAINTENANCE THERAPY WITH SUBCUTANEOUS RISANKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
    Feagan, Brian G.
    Panes, Julian
    Ferrante, Marc
    Kaser, Arthur
    D'Haens, Geert R.
    Sandborn, William J.
    Louis, Edouard
    Neurath, Markus
    Franchimont, Denis
    Dewit, Olivier
    Seidler, Ursula
    Kim, Kyung-Jo
    Selinger, Christian
    Padula, Steven J.
    Herichova, Ivona
    Robinson, Anne M.
    Wallace, Kori
    Zhao, Jun
    Soaita, Adina
    Visvanathan, Sudha
    Hall, David
    Bocher, Wulf O.
    GASTROENTEROLOGY, 2017, 152 (05) : S1310 - S1310
  • [22] An open-label phase 2a study investigating the efficacy and safety of a cathepsin S inhibitor in patients with moderate-to-severe psoriasis
    Gadola, Stephan D.
    Farber, Petra
    Posch, Maximilian G.
    Nagel, Sandra
    Canducci, Filippo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (05) : 1089 - 1091
  • [23] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
    Valenzuela, F.
    Korman, N. J.
    Bissonnette, R.
    Bakos, N.
    Tsai, T. -F.
    Harper, M. K.
    Ports, W. C.
    Tan, H.
    Tallman, A.
    Valdez, H.
    Gardner, A. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 853 - 862
  • [24] A randomized, multicenter, open-label study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate-to-severe Crohn's disease
    不详
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2005, 41 (04): : 539 - 539
  • [25] Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis
    Kang, Eunhye G.
    Narayana, Poornima Krishnamurthy
    Pouliquen, Isabelle J.
    Lopez, Monica C.
    Ferreira-Cornwell, M. Celeste
    Getsy, John A.
    ALLERGY, 2020, 75 (04) : 950 - 953
  • [26] Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study
    Weiner, Daniel E.
    Vervloet, Marc G.
    Walpen, Sebastian
    Schaufler, Thilo
    Munera, Catherine
    Menzaghi, Frederique
    Wen, Warren
    Bhaduri, Sarbani
    Germain, Michael J.
    KIDNEY MEDICINE, 2022, 4 (10)
  • [27] Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study
    Tsai, T. F.
    Liu, M. T.
    Liao, Y. H.
    Licu, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2008, 22 (03) : 345 - 352
  • [28] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Open-Label Extension (OLE) study
    Blauvelt, A.
    Wollenberg, A.
    Chen, Z.
    Bastian, M.
    Zhang, M.
    Khokhar, F. A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 65 - 66
  • [29] Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    de Bruin-Weller, Marjolein
    Chen, Zhen
    Khokhar, Faisal A.
    Zhang, Meng
    Ozturk, Zafer E.
    Shumel, Brad
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1608 - 1616
  • [30] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Paller, Amy S.
    Flohr, Carsten
    Eichenfield, Lawrence F. F.
    Irvine, Alan D. D.
    Weisman, Jamie
    Soung, Jennifer
    Correia, Ana Pinto
    Natalie, Chitra R. R.
    Capriles, Claudia Rodriguez
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Tubau, Clara Armengol
    Laquer, Vivian
    Weidinger, Stephan
    DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
12345